Anavex Life Sciences has announced encouraging results from their recent phase 2b/3 trial for
blarcamesine, a potential treatment for early Alzheimer’s disease. This
investigational therapy appears to significantly reduce amyloid-ß biomarkers, a
hallmark of Alzheimer’s pathology, providing new hope for patients with the disease.
The trial involved 508 participants across five countries and was designed as a double-blind,
placebo-controlled study. Participants received either blarcamesine or a
placebo for 48 weeks. The study’s primary endpoints focused on cognitive and
functional efficacy, utilizing the Alzheimer’s Disease Assessment
Scale-Cognitive (ADAS-Cog) and Alzheimer’s Disease Cooperative Study-Activities
of Daily Living (ADCS-ADL) subscales.
Blarcamesine demonstrated a notable reduction in brain volume loss, including in the whole
brain, compared to placebo. Importantly, the plasma Aβ42/40 ratio, a validated
biomarker of amyloid-ß pathology, showed significant improvement in the
blarcamesine group. These findings suggest that blarcamesine by Anavex, may slow cognitive decline and neurodegeneration, critical factors in
Alzheimer’s disease progression.
While the results are promising, it’s important to note the occurrence of treatment-emergent
adverse events. Dizziness was the most commonly reported side effect, affecting
over a third of those receiving blarcamesine during the titration phase.
However, this adverse event was generally mild to moderate in severity.
Anavex Life Sciences continues to push forward in the development of effective Alzheimer’s
treatments, highlighting their commitment to addressing neurodegenerative
diseases. Dr. Christopher U Missling, CEO of Anavex, expressed gratitude to all
study participants and emphasized the potential of blarcamesine as a
convenient, orally administered therapy for Alzheimer’s patients.
As these trials progress, the medical community will be closely watching Anavex’s efforts,
which could pave the way for new, effective treatment options in the fight
against Alzheimer’s disease. Read this article for more information.
Follow their page on https://www.instagram.com/anavexlifesci/